Category: Press Releases

Genprex announces new branding

Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.

Read More

Genprex announces patent award

Composition of Matter Patent Covers Broad Therapeutic and Diagnostic Applications

Read More

Genprex Announces Patent Award for Cancer Suppressors

AUSTIN, TX, June 28, 2011 – Genprex, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. U.S. Patent No. 7,902,441 is one of 23 patents

Read More

Clinical Trial Data Presented at the 2011 AACR Meeting

Oncoprex™ Phase I clinical trial data presented at the 2011 Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Dr Charles Lu of MD Anderson Cancer Center presented the award winning abstract and poster describing the phase I

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link